Amanote Research
Register
Sign In
PMO-145 Ethnicity Has No Impact on SVR Rates in Patients With HCV Genotype 3 Treated With Pegylated Interferon and Ribavirin: Abstract PMO-145 Figure 1
Gut
- United Kingdom
doi 10.1136/gutjnl-2012-302514b.145
Full Text
Open PDF
Abstract
Available in
full text
Categories
Gastroenterology
Date
May 28, 2012
Authors
A Evans
D Linzey
J Booth
Publisher
BMJ
Related search
Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads
Gastroenterology
Hepatology
Gastroenterology
PMO-144 Experience of Managing Patients With Hepatitis C in Outreach: Abstract PMO-144 Table 1
Gut
Gastroenterology
IL28B Polymorphism Is Not Associated With HCV Protease Diversity in Patients Co-Infected With HIV and HCV Treated With Pegylated Interferon and Ribavirin
Journal of Medical Virology
Virology
Infectious Diseases
Depressive Episode Incidence in Patients With Chronic Hepatitis C Treated With Pegylated Interferon and Ribavirin
Arquivos de Gastroenterologia
Gastroenterology
Dermatological Manifestations of Pegylated Interferon Alfa2a and Ribavirin Combination Therapy in Chronic HCV Patients
Afro-Egyptian Journal of Infectious and Endemic Diseases
Ribavirin Dosage in Patients With HCV Genotypes 2 and 3 Who Completed Short Therapy With Peg-Interferon Α-2b and Ribavirin
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
PMO-167 Presence of Viable HCV RNA in Monocytes at the End of Treatment Predicts Relapse in Genotype 3 HCV Infection
Gut
Gastroenterology
A Case of Chronic Hepatitis C, Genotype 3b Relapsed After Interferon Monotherapy, Treated With Pegylated Interferon Plus Ribavirin and Achieved Sustained Virological Response
Acta Hepatologica Japonica
Hepatology
PMO-220 Patient Anticipation of Some Pain Goes Along Way When Predicting Overall Satisfaction With a Colonoscopy Procedure: Abstract PMO-220 Table 1
Gut
Gastroenterology